If AGR2 antibody and PD-1/PD-L1 inhibitors are combined to form a bispecific antibody, taking advantage of the increased expression of AGR2 in tumor cells, AGR2 antibody targets the tumor microenvironment and guides PD-1/PD-L1 inhibitors to enrich in the tumor bodies, thus reducing the non-specific over-activation of the immune system and maintaining the original or even additional tumor killing effect. Here, CD274 is linked to neoplasm.